摘要
目的 探讨非酒精性脂肪性肝病患者接受微生态制剂口服治疗的临床价值。方法 选取非酒精性脂肪性肝病患者１００例为研究对象，对临床资料进行回顾性分析，根据患者治疗方法的不同分为两组，接受基础治疗患者５０例为对照组，在基础治疗上加用微生态制剂口服治疗５０例为观察组，分析两组疗效。结果 观察组总有效率（５４．００％）明显高于对照组（３０．００％）（χ2＝５９１１，Ｐ＝００１５）；治疗后，观察组丙氨酸氨基转移酶（ＡＬＴ）、甘油三酯（ＴＧ）、稳定胰岛素抵抗指数（ＨＯＭＡ-Ｒ）、肿瘤坏死因子α（ＴＮＦ-α）、Ｄ乳酸、内毒素水平均明显优于对照组（均Ｐ＜０．０５）；两组不良反应发生率差异无统计学意义（４００％比２．００％，χ２ ＝０３４３，Ｐ＝０．５５８）。结论 微生态制剂口服治疗非酒精性脂肪性肝病，可以降低患者的肠黏膜通透性，改善肠源性内毒素血症，促进患者预后的改善。
Objective To investigate the clinical value of probiotics in the treatment of patients with nonal- coholic fatty liver disease （NAFLD）. Methods The clinical data of 100 patients with NAFLD were retrospectively analyzed. According to different treatment methods, the patients were divided into two groups, with 50 cases in each group. The control group received basic treatment, the observation group received probiotics treatment on the basis of the control group. The treatment effects of the two groups were analyzed. Results The total effective rate in the obser- vation group （54.00%） was significantly higher than that in the control group （ 30.00% ） （ X2 = 5. 911, P = 0. 015 ）. After treatment, the ALT, TG, HOMA - R, TNF - α, D - lactic acid, endotoxin levels in the observation group were significantly better than those in the control group （ all P 〈 0. 05 ）. The incidence rate of adverse reactions between the two groups had no statistically significant difference （4.00% vs. 2.00%, X2 = 0. 343, P = 0. 558 ）. Conclusion Probiotics in the treatment of NAFLD can reduce the intestinal permeability, improve the intestinal endotoxemia and the prognosis of the patients.
作者
夏晨梅
陈霞
李倩倩
金玲肖
Xia Chenmei;Chen Xia;Li Qianqian;Jin Lingxiao(Department of Gastroenterology, the First People＇s Hospital of Wenling , Wenling , Zhejiang 317500, China)
出处
《中国基层医药》
CAS
2018年第10期1234-1237,共4页
Chinese Journal of Primary Medicine and Pharmacy
基金
浙江省温岭市科技计划社会项目（2016C31BA0058）
关键词
脂肪肝
胃肠道
微生物学技术
内毒素类
Fatty liver
Gastrointestinal tract
Microbiological techniques
Endotoxins
